Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis

Journal of Cutaneous Pathology

Volumn 37, Issue 1, 2010, Pages 94-98

  Turza, Kristin ^a   Dengel, Lynn T ^a   Harris, Rebecca C ^a   Patterson, James W ^a   White, Kevin ^a   Grosh, William W ^a   Slingluff Jr , Craig L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; PEPTIDE VACCINE;

ADULT; ANAMNESIS; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CASE REPORT; DIAGNOSTIC IMAGING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MELANOMA; MELANOSIS; METASTASIS; SKIN BIOPSY; SKIN INFLAMMATION;

ADMINISTRATION, CUTANEOUS; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; DERMIS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; SUBCUTANEOUS TISSUE; TREATMENT OUTCOME;

EID: 71049119365     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2009.01290.x     Document Type: Article

References (15)

1. Woodmansee C, Pillow J, et al. The role of topical immune response modifiers in skin cancer. Drugs 2006 66 : 1657.
2. Ugurel S, Wagner A, et al. Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread. Br J Dermatol 2002 147 : 621.
3. Bong AB, Bonnekoh B, et al. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 2002 205 : 135.
4. Steinmann A, JO Funk JO, et al. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000 43 : 555.
5. Cotter MA, McKenna JK, et al. Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg 2008 34 : 147.
6. Rajpar SF, Marsden JR. Imiquimod in the treatment of lentigo maligna. Br J Dermatol 2006 155 : 653.
7. Spenny ML, Walford J, et al. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. Cutis 2007 79 : 149.
8. du Plessis PJ. Lentigo maligna successfully treated with imiquimod. S Afr J Surg 2007 45 : 72.
9. Vereecken P, Mathieu A, et al. Management of cutaneous locoregional recurrences of melanoma: a new therapeutic perspective with imiquimod. Dermatology 2003 206 : 279.
10. Wolf IH, Smolle J, et al. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003 139 : 273.
11. Fraker DL, Alexander HR, et al. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Cancer J Sci Am 1995 1 : 122.
12. Fraker DL, Alexander HR, et al. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996 14 : 479.
13. Feldman AL, Alexander HR Jr., et al. Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. Ann Surg Oncol 1999 6 : 562.
14. Utikal J, Zimpfer A, et al. Complete remission of multiple satellite and in-transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod. Br J Dermatol 2006 155 : 488.
15. Green DS, Bodman-Smith MD, et al. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007 156 : 337.